Investor Presentaiton

SAR-bisPSMA therapy in prostate cancer SECURE: Systemic Copper theranostics in prostate cancer • Phase I/lla study of 64 Cu/67 Cu SAR-bisPSMA for identification and treatment of PSMA-expressing metastatic castrate resistant prostate cancer (mCRPC) • Principal Investigators: Dr Scott Tagawa/Dr Geoff Johnson Trial design Theranostic multi-centre, single arm, dose escalation study with a cohort expansion planned for up to 44 patients Dosimetry phase (N=6) Dose escalation Dose expansion phase (N=~24) phase (N=14) Status Dosimetry phase with 64CU SAR-bisPSMA in mCRPC completed Dose escalation now open for recruitment Next milestone • First therapy patient treated - estimate June 2022 CLARITY 2014 M SECURE Preliminary imaging results from the dosimetry phase 64CU SAR-bisPSMA PET/CT Comparison of 1h 64CU SAR-bisPSMA PET with 99mTc-MDP Bone Scan 12hr 64CU SAR- bisPSMA PET/CT 1h 64CU SAR- bisPSMA PET 99mTc-MDP WB Bone Scan Fused Sagittal SECURE clinicaltrials.gov identifier: NCT04868604 13

View entire presentation